SCHEDULE: Vanguard Group Divests BioLife Solutions Stake

The Vanguard Group reports zero beneficial ownership in BioLife Solutions Inc. common stock following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 3 to Schedule 13G for BioLife Solutions Inc. common stock.
• The filing reports 0 shares beneficially owned by The Vanguard Group, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for BioLife Solutions, as it primarily reflects an internal organizational and reporting change by The Vanguard Group rather than a change in investment thesis or performance.

Future Outlook

The Vanguard Group's subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors. This specific amendment reflects an internal organizational change at Vanguard rather than a change in investment strategy regarding BioLife Solutions by Vanguard's overall managed funds.

Stakeholder Impact

• Shareholders of BioLife Solutions: No direct impact on company operations or value, but a major institutional investor (Vanguard) is no longer reporting direct beneficial ownership, which might be misinterpreted without context.

Key Dates

Recommendation

This filing indicates an internal organizational change by The Vanguard Group, resulting in them no longer reporting direct beneficial ownership of BioLife Solutions common stock. It does not reflect a change in BioLife Solutions' fundamentals or performance, nor does it necessarily imply a divestment by Vanguard's managed funds overall. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

BioLife Solutions Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Investment Management